11 ß-HSD1 Lentiviral Activation Particles

• Description:

  11 ß-HSD1 Lentiviral Activation Particles_x000D_ Catalog number: B2015137_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 100 µL_x000D_ Molecular Weight or Concentration: N/A_x000D_ Supplied as: Solution_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -80¬∞C_x000D_ Keywords: 11 ß-HSD1 Lentiviral Activation Particles_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Liu H, Li L, Zhang C, Li H, Liu J, Tang C, Zhang Y, Wu D, Chu Y, Wu Y, Yuan X. 11 ß-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Development by Lentiviral Screening Based on Computational Modeling Pharmacology. 2018;102(3-4):169-179._x000D_ 2: Wu L, Qi H, Zhong Y, Lv S, Yu J, Liu J, Wang L, Bi J, Kong X, Di W, Zha J, Liu F, Ding G. 11 ß-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction Endocr J. 2013;60(9):1047-58._x000D_ 3: Li H, Hu S, Wu R, Zhou H, Zhang K, Li K, Lin W, Shi Q, Chen H, Lv S. 11 ß-Hydroxysteroid Dehydrogenase Type 1 Facilitates Osteoporosis by Turning on Osteoclastogenesis through Hippo Signaling Int J Biol Sci. 2023 Jul 15;19(11):3628-3639._x000D_ 4: Taves MD, Otsuka S, Taylor MA, Donahue KM, Meyer TJ, Cam MC, Ashwell JD. Tumors produce glucocorticoids by metabolite recycling, not synthesis, and activate Tregs to promote growth J Clin Invest. 2023 Sep 15;133(18):e164599._x000D_ 5: Dineen RA, Martin-Grace J, Ahmed KMS, Taylor AE, Shaheen F, Schiffer L, Gilligan LC, Lavery GG, Frizelle I, Gunness A, Garrahy A, Hannon AM, Methlie P, Eystein SH, Stewart PM, Tomlinson JW, Hawley JM, Keevil BG, O'Reilly MW, Smith D, McDermott J, Healy ML, Agha A, Pazderska A, Gibney J, Behan LA, Thompson CJ, Arlt W, Sherlock M. Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy J Clin Endocrinol Metab. 2023 Nov 17;108(12):3178-3189._x000D_ 6: Peng K, Pan Y, Li J, Khan Z, Fan M, Yin H, Tong C, Zhao Y, Liang G, Zheng C. 11 ß-Hydroxysteroid Dehydrogenase Type 1(11 ß-HSD1) mediates insulin resistance through JNK activation in adipocytes Sci Rep. 2016 Nov 14;6:37160._x000D_ 7: Tsai KH, Cooper MS. Recycling glucocorticoids: therapeutic implications of the 11 ß-HSD1 enzyme system J Endocrinol. 2023 Aug 1;258(3):e220289._x000D_ 8: Gathercole LL, Lavery GG, Morgan SA, Cooper MS, Sinclair AJ, Tomlinson JW, Stewart PM. 11 ß-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects Endocr Rev. 2013 Aug;34(4):525-55._x000D_ 9: Gray GA, White CI, Castellan RF, McSweeney SJ, Chapman KE. Getting to the heart of intracellular glucocorticoid regeneration: 11 ß-HSD1 in the myocardium J Mol Endocrinol. 2017 Jan;58(1):R1-R13._x000D_ 10: Chuanxin Z, Shengzheng W, Lei D, Duoli X, Jin L, Fuzeng R, Aiping L, Ge Z. Progress in 11 ß-HSD1 inhibitors for the treatment of metabolic diseases: A comprehensive guide to their chemical structure diversity in drug development Eur J Med Chem. 2020 Apr 1;191:112134. _x000D_ _x000D_ Products Related to 11 ß-HSD1 Lentiviral Activation Particles can be found at Chemicals

• Short Description:

  Catalog Number: B2015137 (100 µL)

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height:

  0.5

• Height :

  0.5